For a subset of NSCLC patients with the echinoderm microtubule protein like-4/anaplastic lymphoma kinase (EML-4/ALK) translocation, crizotinib is approved by the FDA as a second-line therapy. Here, ALK is linked to non-small cell lung carcinoma.